Yongfeng He, PhD, is an instructor of cancer biology in medicine at Weill Cornell Medicine in New York, New York.

He, along with Giuseppe Gianccone, MD, PhD, professor of medicine and associate director of clinical research at the Sandra and Edward Meyer Cancer Center at Weill Cornell, discovered that the presence of the 

 L424H mutation in thymic epithelial cells induced thymic tumors in mouse models. The mouse tumors shared many molecular characteristics with type B1 and B2 human thymic tumors.

 L424H is a transcription factor so it is unlikely to be a therapeutic target. However, this discovery may be the first step in developing a systemic treatment for patients with thymic cancers.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Thymic Cancers

OncLive®'s Rare Cancer Series is a monthly spotlight on a rare malignancy for which patients have limited treatment options and large unmet needs exist. The Rare Cancer Series includes articles, interviews in written and video format, and podcasts that are all focused on learning more about these less common malignancies and how to therapeutically approach patients. 

Rare Cancer Series

Yongfeng He, PhD, discusses how the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models.

Dr. He Discusses Potential Therapeutic Uses for GTF2I L424+ Thymic Cancers